Skip to main content
. 2022 Aug 3;9(6):3737–3750. doi: 10.1002/ehf2.14097

Figure 2.

Figure 2

Effectiveness of sacubitril/valsartan compared with ACEi/ARBs in chronic HFrEF in randomized clinical trials and real‐world practice. ACEi, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CV, cardiovascular; HFrEF, heart failure with reduced ejection fraction; HHF, heart failure hospitalization.